MONALEESA-3 Phase 3 trial

June 4, 2020June 4, 2020

Kisqali Prolongs Overall Survival in Advanced Breast Cancer Patients with Internal Organ Metastases

News

Kisqali (ribociclib) combined with endocrine therapy prolongs the overall survival of women with HR-positive, HER2-negative, advanced or metastatic breast cancer with visceral metastases (in the soft internal organs), data from two ... Read more

October 16, 2019

Kisqali-Faslodex Combo Prolongs Survival of Postmenopausal Women with Advanced Breast Cancer, Phase 3 Trial Shows

News

Kisqali (ribociclib) in combination with Faslodex (fulvestrant) prolongs the survival of postmenopausal women with HR-positive, HER2-negative, advanced or metastatic breast cancer, interim analysis of a Phase 3 clinical trial shows. ... Read more